- Price
- $32.94
- Day
- +1.01%
- Mkt Cap
- $3.84B
- 52W Range
- $22.96 – $43.15
- Volume
- 1.67M
- Beta
- 0.66
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.
Read full article
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH 1 & 2 Trials for Subcutaneous VK2735 in Obesity Fully Enrolled and Advancing -- -- Oral Phase 3 VK2735 Trial Initiation Expected 4Q26 -- -- VK2735 Maintenance Dosing Data Expected 3Q26 -- -- Phase 1 Study of Amylin Agonist VK3019 Underway -- -- Strong Quarter-End Cash Position of $502 Million -- SAN DIEGO, July 29, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2026, and provided an update on its clinical pipeline and other corporate developments.
Read full article
Biotech is setting up as one of the more interesting risk-on trades heading into the back half of 2026.
Read full article
Viking Therapeutics NASDAQ: VKTX reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735, through Phase III development in injectable and planned oral formulations.
Read full article
Viking Therapeutics, Inc. (VKTX) Q2 2026 Earnings Call Transcript
Read full article
Viking Therapeutics has a promising pipeline candidate in late-stage studies. Positive results from ongoing phase 3 trials could send the stock soaring.
Read full article
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read full article
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Read full article
Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the appointment of Dorothy Gemmell to its Board of Directors, effective immediately. Ms. Gemmell is a highly experienced executive and board advisor with over 25 years of leadership experience across healthcare, digital health, and commercialization.
Read full article
Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close.
Read full article
Conference Call Scheduled for Wednesday, July 29, at 4:30 p.m. Eastern Time SAN DIEGO, July 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the second quarter of 2026 after the market close on Wednesday, July 29, 2026.
Read full article
NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Read full article